去氨加压素对接受神经外科干预的自发性抗血小板相关脑出血患者临床结局的影响:一项观察性多中心研究
该多中心观察性研究纳入2016年1月至2023年11月急诊科收治的75例接受抗血小板治疗并需神经外科干预的自发性脑出血患者,其中去氨加压素组26例、对照组49例。经逆概率治疗加权调整后基线无显著差异,出院时mRS 4-6比例去氨加压素组84.3% vs 对照组88.2%(P=0.692),无显著差异。多变量广义估计方程logistic回归显示去氨加压素与功能结局、安全性结局及院内和随访结局均无显著关联。作者结论为两组出院mRS及严重不良事件无显著差异,但因研究把握度不足,该阴性结果需谨慎解读,需进一步随机对照试验验证。
要点
- 接受抗血小板治疗并需神经外科干预的自发性脑出血患者中,术前去氨加压素组出院mRS 4-6为84.3%,对照组为88.2%(P=0.692),无显著差异。
- 多变量广义估计方程logistic回归显示去氨加压素与功能结局、安全性结局、院内及随访结局均无显著关联。
- 共纳入75例患者,去氨加压素组26例、对照组49例,经逆概率治疗加权调整后基线特征无显著差异。
- 作者指出该阴性结果因研究把握度不足需谨慎解读,需进一步随机对照试验验证。
适用人群与场景
- 2016年1月至2023年11月急诊科收治的自发性脑出血并接受抗血小板治疗、需神经外科干预的患者。
- 排除创伤性脑损伤、蛛网膜下腔出血所致脑出血、动静脉畸形、颅内肿瘤、凝血病及使用抗凝药的患者。
处置流程与药物剂量
- 去氨加压素组术前接受去氨加压素乙酸酯(DDAVP)给药,对照组未给予;原文未报告具体剂量、途径、频次及疗程。
研究设计与关键结果
- 多中心观察性研究,纳入75例接受抗血小板治疗并需神经外科干预的自发性脑出血患者,去氨加压素组26例 vs 对照组49例。
- 主要终点出院时mRS 4-6:去氨加压素组84.3% vs 对照组88.2%,P=0.692,无显著差异。
- 经逆概率治疗加权调整后基线特征无显著差异;多变量广义估计方程logistic回归显示去氨加压素与功能结局、安全性结局、院内及随访结局均无显著关联。
- 作者结论为两组出院mRS及严重不良事件无显著差异,但该阴性结果因研究把握度不足需谨慎解读,需进一步随机对照试验验证。
证据类型、等级与局限
- 证据类型:多中心观察性研究。
- 局限:作者指出研究把握度不足(underpowered),阴性结果需谨慎解读,需进一步随机对照试验验证。
对床旁实践的改变
- 作者认为,在该接受抗血小板治疗并需神经外科干预的自发性脑出血人群中,术前去氨加压素与未给予相比出院mRS 4-6及严重不良事件无显著差异,但因研究把握度不足,该阴性结果需谨慎解读。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Managing surgical cases of acute spontaneous intracerebral hemorrhage (ICH) in patients with antiplatelet therapy presents significant challenges due to the heightened risk of bleeding. Desmopressin acetate (DDAVP) is commonly employed as a management strategy. This multicenter study aims to compare the functional and safety outcomes in patients with or without preoperative DDAVP administration after spontaneous antiplatelet-associated ICH.
METHODS: From January 2016 to November 2023, we enrolled patients with spontaneous ICH who were under antiplatelet therapy and needed neurosurgical interventions in the emergency departments. Patients were excluded for traumatic brain injury, ICH from subarachnoid hemorrhage, arteriovenous malformation, intracranial tumors, coagulopathies, and anticoagulant use. The primary outcome was the modified Rankin Scale (mRS) 4-6 at discharge. Secondary endpoints included safety outcomes and in-hospital and follow-up outcomes.
RESULTS: A total of 75 patients were included, comprising 26 patients treated with DDAVP and 49 patients in the control group. After inverse probability of treatment weighting adjustment, there were no significant differences in baseline characteristics. There were no significant differences in mRS of 4-6 at discharge between groups (84.3% vs. 88.2%; P = 0.692). Multivariable generalized estimating equations logistic regression demonstrated DDAVP was not significantly associated with improved functional outcome, safety outcomes, or in-hospital or follow-up outcomes.
CONCLUSIONS: This study demonstrated no significant difference in mRS at discharge or serious adverse events between patients with and without DDAVP administration. However, this null finding should be interpreted cautiously due to the study being underpowered. Further randomized controlled trials are warranted to validate our findings.
参考来源
- Hsu PT, Chien SC, Chen CC, et al. Impact of Desmopressin on Clinical Outcomes in Patients with Spontaneous Antiplatelet-Associated Intracerebral Hemorrhage Undergoing Neurosurgical Intervention: An Observational Multicenter Study. Shock. 2025. PMID: 40961383. doi:10.1097/SHK.0000000000002694
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。